Werewolf Therapeutics
HOWL
69 hedge funds and large institutions have $68.3M invested in Werewolf Therapeutics in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 14 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
1.01% less ownership
Funds ownership: 74.71% → 73.7% (-1%)
3% less funds holding
Funds holding: 71 → 69 (-2)
14% less capital invested
Capital invested by funds: $79.2M → $68.3M (-$10.9M)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$486K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$385K |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$359K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$221K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$209K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$571K |
| 2 |
HF
HRT Financial
New York
|
-$481K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$477K |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$407K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$327K |
HOWL Hedge Fund Activity: Q3 2024 in Review
69 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q3 2024, worth a combined $68.3M — down 14% from $79.2M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of HOWL and 12 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 27 added.
The largest buyer was Millennium Management, adding an estimated $486K. The largest seller was Verition Fund Management, exiting entirely with an estimated $571K sold.
- 69 institutional investors held Werewolf Therapeutics (HOWL) as of Q3 2024, down from 71 in Q2 2024.
- Funds reported $68.3M of Werewolf Therapeutics stock for Q3 2024, down 14% quarter-over-quarter.
- 12 funds opened new Werewolf Therapeutics positions in Q3 2024 and 14 closed out, a net change of -2 holders.
- The largest Werewolf Therapeutics buyer in Q3 2024 was Millennium Management, an estimated $486K added.
- The largest Werewolf Therapeutics seller in Q3 2024 was Verition Fund Management, an estimated $571K sold.
Based on aggregated 13F filings for Q3 2024.